TY  - BOOK
AU  - Kareff, Samuel
AU  - Kim, Chul
TI  - Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
SN  - 2051-1426
PY  - 2021///
KW  - *Carcinoma, Large Cell/dt [Drug Therapy]
KW  - *Carcinoma, Neuroendocrine/dt [Drug Therapy]
KW  - *Immune Checkpoint Inhibitors/tu [Therapeutic Use]
KW  - *Lung Neoplasms/dt [Drug Therapy]
KW  - Aged
KW  - Carcinoma, Large Cell/im [Immunology]
KW  - Carcinoma, Large Cell/mo [Mortality]
KW  - Carcinoma, Large Cell/sc [Secondary]
KW  - Carcinoma, Neuroendocrine/im [Immunology]
KW  - Carcinoma, Neuroendocrine/mo [Mortality]
KW  - Carcinoma, Neuroendocrine/sc [Secondary]
KW  - District of Columbia
KW  - Female
KW  - Humans
KW  - Immune Checkpoint Inhibitors/ae [Adverse Effects]
KW  - Israel
KW  - Lung Neoplasms/im [Immunology]
KW  - Lung Neoplasms/mo [Mortality]
KW  - Lung Neoplasms/pa [Pathology]
KW  - Male
KW  - Middle Aged
KW  - Retrospective Studies
KW  - Risk Assessment
KW  - Risk Factors
KW  - Time Factors
KW  - Treatment Outcome
KW  - Tumor Microenvironment
KW  - MedStar Washington Hospital Center
KW  - Washington Cancer Institute
KW  - Medicine/Internal Medicine
KW  - Journal Article
N2  - BACKGROUND: Little is known regarding the efficacy of immune checkpoint inhibitors (ICI) in patients with advanced large-cell neuroendocrine lung carcinoma (aLCNEC); CONCLUSIONS: With the limitations of retrospective design and small sample size, the results of this real-world cohort analysis suggest a positive impact of ICI on OS in aLCNEC. Copyright (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ; METHODS: 125 consecutive patients with aLCNEC were identified in the electronic databases of 4 participating cancer centers. The patients were divided into group A (patients who received ICI, n=41) and group B (patients who did not receive ICI, n=84). Overall survival since advanced disease diagnosis (OS DX) and OS since ICI initiation (OS ICI) were captured; RESULTS: With a median follow-up of 11.8 months (mo) (IQR 7.5-17.9) and 6.0mo (IQR 3.1-10.9), 66% and 76% of patients died in groups A and B, respectively. Median OS DX was 12.4mo (95% CI 10.7 to 23.4) and 6.0mo (95% CI 4.7 to 9.4) in groups A and B, respectively (log-rank test, p=0.02). For ICI administration, HR for OS DX was 0.59 (95% CI 0.38 to 0.93, p=0.02-unadjusted), and 0.58 (95% CI 0.34 to 0.98, p=0.04-adjusted for age, Eastern Cooperative Oncology Group (ECOG) performance status (PS), presence of liver metastases and chemotherapy administration). In a propensity score matching analysis (n=74; 37 patients in each group matched for age and ECOG PS), median OS DX was 12.5 mo (95% CI 10.6 to 25.2) and 8.4 mo (95% CI 5.4 to 16.9) in matched groups A and B, respectively (log-rank test, p=0.046). OS ICI for patients receiving ICI as monotherapy (n=36) was 11.0 mo (95% CI 6.1 to 19.4)
UR  - https://dx.doi.org/10.1136/jitc-2020-001999
ER  -